Disease · MONDO_0003219

gastroesophageal junction adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastroesophageal junction adenocarcinoma. Diseases, record MONDO_0003219. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003219

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastroesophageal junction adenocarcinoma; Open Targets
Open Targets ID: MONDO_0003219; Open Targets
Other names: adenocarcinoma - GEJ, adenocarcinoma of cardioesophageal junction, adenocarcinoma of gastroesophageal junction, adenocarcinoma of the EG junction, adenocarcinoma of the GE junction, adenocarcinoma of the cardioesophageal junction, adenocarcinoma of the esophagogastric junction, adenocarcinoma of the gastroesophageal junction, esophagogastric junction adenocarcinoma; Open Targets
Disease Ontology: DOID:4944; Disease Ontology
NCI Thesaurus: C9296; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 178 drugs, from ClinicalTrials.gov and FDA; Open Targets

Drugs178

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Approval	ClinicalTrials.gov	85	85	77	Drugs and targets
RAMUCIRUMAB	CHEMBL1743062	Antibody	Approval	ClinicalTrials.gov	40	40	40	Drugs and targets
ZOLBETUXIMAB	CHEMBL2109427	Antibody	Approval	FDA	8	7	7	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	213	213	206	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	124	124	122	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	106	106	99	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	62	62	62	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	50	50	50	Drugs and targets
S1?	CHEMBL4525128		Phase 3	ClinicalTrials.gov	45	45	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	42	42	42	Drugs and targets

1 to 10 of 178

See all 178 drugs

Targets215

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	15	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	12	Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent	Phase 3	https://conductscience.org/library/genes/2064	Drugs and targets
KDR	Vascular endothelial growth factor receptor	12	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
EGFR	Epidermal growth factor receptor	10	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	9	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	7	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	7	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 215

See all 215 targets

Trials497

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3	2,031	2022-06-28	Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma	CAPECITABINE, FLUOROURACIL, IPILIMUMAB, LEUCOVORIN CALCIUM, NIVOLUMAB, OXALIPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03221426	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)	Phase 3	1,007	2025-02-20	Gastric Cancer, Gastroesophageal Junction Cancer	CAPECITABINE, CISPLATIN, DOCETAXEL, FLUOROURACIL, OXALIPLATIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03777657	Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma	Phase 3	997	2025-02-14	Gastric, or Gastroesophageal Junction Adenocarcinoma	CAPECITABINE, CISPLATIN, FLUOROURACIL, OXALIPLATIN, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00678535	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer	Phase 3	904	2013-05-16	Gastric Cancer	CAPECITABINE, CETUXIMAB, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02494583	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	Phase 3	763	2020-03-13	Gastric Adenocarcinoma	CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03615326	Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)	Phase 3	738	2025-03-17	Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma	CAPECITABINE, CISPLATIN, FLUOROURACIL, OXALIPLATIN, PEMBROLIZUMAB, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02178956	A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer	Phase 3	714	2021-05-10	Gastric Cancer, Gastroesophageal Junction Cancer	NAPABUCASIN	Its record names the disease	ClinicalTrials.gov
NCT01170663	A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma	Phase 3	665	2014-07-31	Gastric Cancer	PACLITAXEL, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT02314117	A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	Phase 3	645	2018-05-02	Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	CAPECITABINE, CISPLATIN, FLUOROURACIL, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT02564263	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)	Phase 3	628	2019-11-20	Esophageal Carcinoma, Esophagogastric Junction Carcinoma	DOCETAXEL, IRINOTECAN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 497

See all 497 trials

Comparisons in its trials80

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: deaths from any cause	397 of 501	431 of 496	997	NCT03777657	Trial comparisons
Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: serious adverse events	211 of 498	179 of 494	992	NCT03777657	Trial comparisons
Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin: Safety - Number of Participants With Adverse Events (AEs)	446 of 446	432 of 436	882	NCT00678535	Trial comparisons
Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin: serious adverse events	239 of 446	194 of 436	882	NCT00678535	Trial comparisons
Napabucasin + Paclitaxel vs Placebo + Paclitaxel: Number of Patients With Adverse Events	352 of 357	338 of 350	707	NCT02178956	Trial comparisons
Napabucasin + Paclitaxel vs Placebo + Paclitaxel: deaths from any cause	286 of 357	275 of 350	707	NCT02178956	Trial comparisons
Napabucasin + Paclitaxel vs Placebo + Paclitaxel: serious adverse events	125 of 357	101 of 350	707	NCT02178956	Trial comparisons
Ramucirumab and Paclitaxel vs Placebo and Paclitaxel: serious adverse events	161 of 327	146 of 329	656	NCT01170663	Trial comparisons
Ramucirumab + Cisplatin + Capecitabine vs Placebo + Cisplatin + Capecitabine: Number of Participants With Anti-Ramucirumab Antibodies	4 of 323	5 of 315	638	NCT02314117	Trial comparisons
LY3009806+Capecitabine+Cisplatin vs Placebo+Capecitabine+Cisplatin: serious adverse events	161 of 323	150 of 315	638	NCT02314117	Trial comparisons

1 to 10 of 80

See all 80 comparisons in its trials

Papers from its trials266

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41653501	RESULT	1	PubMed
39383487	RESULT	2	PubMed
39282917	RESULT	1	PubMed
38134948	RESULT	1	PubMed
37963317	RESULT	1	PubMed
37871604	RESULT	1	PubMed
36603169	RESULT	1	PubMed
35969830	RESULT	1	PubMed
35202974	RESULT	1	PubMed
34796431	RESULT	1	PubMed

1 to 10 of 266

See all 266 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003219

GET https://conductscience.org/api/diseases/v1/MONDO_0003219/drugs?page=2

API reference For AI assistants